{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:56:50Z","timestamp":1790776610674,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01627-3","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:07:18Z","timestamp":1790773638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world treatment patterns and outcomes of brentuximab vedotin\u2013based therapy in CD30-positive lymphomas in China: the prospective BRAVE study"],"prefix":"10.1038","volume":"16","author":[{"given":"Ming-Ci","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8558-3131","authenticated-orcid":false,"given":"Hui-Lai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3125-9547","authenticated-orcid":false,"given":"Chuan-Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu-Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9489-5965","authenticated-orcid":false,"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Hui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Qing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-1612","authenticated-orcid":false,"given":"Zheng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-3736","authenticated-orcid":false,"given":"Fang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5057-5919","authenticated-orcid":false,"given":"Xiao-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-8449","authenticated-orcid":false,"given":"Shen-Miao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-4438","authenticated-orcid":false,"given":"Bing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-1014","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Qian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Jie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-1616","authenticated-orcid":false,"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1627_CR1","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018;378:331\u201344.","journal-title":"N Engl J Med"},{"key":"1627_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"key":"1627_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO-24-02242","volume":"43","author":"NL Bartlett","year":"2025","unstructured":"Bartlett NL, Hahn U, Kim WS, Fleury I, Laribi K, Bergua JM, et al. Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol. 2025;43:1061\u201372.","journal-title":"J Clin Oncol"},{"key":"1627_CR4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.annonc.2025.01.023","volume":"36","author":"F d\u2019Amore","year":"2025","unstructured":"d\u2019Amore F, Federico M, de Leval L, Ellin F, Hermine O, Kim WS, et al. Peripheral T- and natural killer-cell lymphomas: ESMO-EHA clinical practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025;36:626\u201344.","journal-title":"Ann Oncol"},{"key":"1627_CR5","unstructured":"NCCN. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Hodgkin Lymphoma. Version 1. 2026. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf."},{"key":"1627_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","volume":"33","author":"J Zhu","year":"2021","unstructured":"Zhu J, Ma J. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version). Chin J Cancer Res. 2021;33:289\u2013301.","journal-title":"Chin J Cancer Res"},{"key":"1627_CR7","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s12672-025-02980-8","volume":"16","author":"L Huang","year":"2025","unstructured":"Huang L, Yang Y, Zhao Z, Zhou S, Wu J, Wang N, et al. Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in China: a multicenter, real-world study. Discov Oncol. 2025;16:1252.","journal-title":"Discov Oncol"},{"key":"1627_CR8","first-page":"1094","volume":"46","author":"Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO); Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association.","year":"2025","unstructured":"Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO); Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association.Chinese expert consensus on the diagnosis and management of nodal peripheral T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2025;46:1094\u2013104.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"1627_CR9","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1007\/s00277-025-06507-7","volume":"104","author":"F Guan","year":"2025","unstructured":"Guan F, Zhang Y, Guo X, Cheng F, Zhang E, He J, et al. Brentuximab vedotin plus CHP-like regimen for the first-line treatment of PTCL patients: a real-world single center study. Ann Hematol. 2025;104:3745\u201351.","journal-title":"Ann Hematol"},{"key":"1627_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41409-025-02557-7","volume":"60","author":"A Sureda","year":"2025","unstructured":"Sureda A, Pavlovsky A, Haidar D, Kristo F, Stache V, Zomas A. Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: a systematic review and meta-analysis. Bone Marrow Transplant. 2025;60:820\u201331.","journal-title":"Bone Marrow Transplant"},{"key":"1627_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1494384","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Yu Q, Su L, He J, Tao J, Xi Y, et al. Real-world experiences with brentuximab vedotion-based regimens in systemic anaplastic large cell lymphoma: a multi-center retrospective study. Front Oncol. 2024;14:1494384.","journal-title":"Front Oncol"},{"key":"1627_CR12","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/HS9.0000000000000052","volume":"2","author":"P Borchmann","year":"2018","unstructured":"Borchmann P, Fossa A, Dlugosz-Danecka M, Boll B, Dietlein M, Kobe C, et al. The Phase 3 Study ECHELON-1 evaluating brentuximab vedotin in patients with newly diagnosed hodgkin lymphoma leaves important questions unanswered. Hemasphere. 2018;2:e52.","journal-title":"Hemasphere"},{"key":"1627_CR13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-019-0223-7","volume":"9","author":"C Lai","year":"2019","unstructured":"Lai C, Kandahari AM, Ujjani C. The evolving role of brentuximab vedotin in classical hodgkin lymphoma. Blood Lymphat Cancer. 2019;9:63\u201371.","journal-title":"Blood Lymphat Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01627-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01627-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01627-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:07:25Z","timestamp":1790773645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01627-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1627"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01627-3","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"17 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.O., Z.H.L., H.W.Y., L.L.H., W.L.Q., S.L.P., Z.W., X.W., D.K.Y., C.G.H., J.H.M., W.X.B., X.B., L.Y., N.T., S.K.Q., Li.C.X., Z.W.L. are members of advisory council\/committees for Takeda; B.O., Z.H.L., Liu.C.X., H.W.Y., L.L.H., L.Z.J., W.L.Q., S.L.P., Z.W., X.W., D.K.Y., C.G.H., J.H.M., W.H.Q., G.Z., Z.F., L.F., W.X.B., Y.S.M., X.B., L.Y., L.Y.F., N.T., S.K.Q., Li.C.X., H.Z.Q., L.H., Q.L., W.S.J., Z.H.Y., Z.W.L. receive honoraria of Takeda; W.J.L. and Z.W.X. are employees of Takeda. This study was funded by Takeda (China) International Trading Co., Ltd., an affiliation of Takeda Pharmaceutical Company.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. The study protocol was approved by the Ethics Committee of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine (approval no. [2021] Ethics No. 2), as well as by the ethics committees at each participating site. The study was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to enrollment.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"167"}}